GlassScriptPhysician profile
Bethany Lucas
NPI 1477792489
$1,404.31
in general payments reported to CMS, 2019-2025
14 companies · $692 in 2025
The $692 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.24 · 2024: $650 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $560.56 | 2024-2025 | |
| Novo Nordisk INC | $195.23 | 2024-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $149.15 | 2024-2025 | Mounjaro, Zepbound, Emgality |
| Aimmune Therapeutics, INC. | $102.66 | 2024-2025 | Zenpep |
| Astellas Pharma US INC | $63.04 | 2024-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $62.24 | 2019 | |
| Pfizer INC. | $52.14 | 2024 | |
| Glaxosmithkline, LLC. | $49.86 | 2024-2025 | Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $45.30 | 2024 | Farxiga, Breztri |
| Axsome Therapeutics, INC. | $33.94 | 2025 | Auvelity |
| Shield Therapeutics INC | $32.88 | 2024 | |
| Esperion Therapeutics, INC. | $25.82 | 2024 | Nexletol |
| Dexcom, INC. | $17.50 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $13.99 | 2024 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Lucas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.